Viatris deal gives Biocon Biologics entry in 100 countries: Shreehas Tambe

In a Q&A, the recently named MD & CEO of Biocon Biologics dwells on the scope for an IPO or stake sale to PE investors to retire the debt taken to fund the acquisition

With Shreehas Tambe having taken over as MD & CEO of Biocon Biologics, after starting as a management trainee in the company back in 1997, the company is working to integrate the Viatris deal it recently struck. Speaking to Sohini Das, the new boss at the company dwells on Biocon Biologics' openness to having an IPO or a stake sale to PE investors to retire the debt taken to fund the deal. Edited excerpts:

You've spent nearly three decades in Biocon. What is your vision now that you are at the helm?

I joined Biocon in 1997. It has been